The Quiet Rise of Litigation Finance
Litigation finance – the practice of third-party investors funding lawsuits in exchange for a share of any eventual settlement or verdict – has spent decades on the margins of institutional investing. That is changing, and the shift is moving fast enough that allocation desks at pension funds and endowments are now treating it as a standalone asset class rather than a curiosity.
Why Institutional Money Is Moving In
The core appeal is structural. Litigation outcomes are not correlated to equity markets, interest rate cycles, or credit spreads. A commercial contract dispute between two corporations does not perform worse because the S&P 500 drops fifteen percent in a quarter. For large allocators hunting for genuine diversification – not just assets that claim to be uncorrelated and then crater alongside equities during a stress event – litigation finance offers something rare: returns that are driven entirely by legal merit, case duration, and the size of judgments, none of which track the business cycle.
The asset class also benefits from a hard asymmetry. When a funded case loses, the investor loses their capital committed to that case. When it wins, the returns can be multiples of the original investment – five times, ten times, or more in cases involving large commercial damages. Funds structure portfolios across dozens of active matters, spreading the binary risk while retaining the upside potential. The math is similar to venture capital in structure, but the underlying variables – statute of limitations, discovery timelines, judicial precedent – are entirely different from startup mortality rates.
Verdicts across commercial litigation have grown materially over the past decade. Patent infringement awards, antitrust damages, and securities fraud settlements have all seen headline numbers climb. This matters directly to funders because their returns are calculated as a percentage of recovery. Larger verdicts mean larger absolute payouts even on the same percentage terms. The growth in “nuclear verdicts” – a legal industry term for awards in the hundreds of millions or billions – has made the asset class more visible to institutional capital that needs to move money in size.
Several dedicated litigation finance managers have scaled to the point where they can absorb commitments from large institutional investors without concentration problems. Funds are now structured with institutional-grade governance, audited financials, and formal risk management frameworks. That infrastructure matters enormously to pension fund trustees and endowment investment committees who face fiduciary scrutiny on every allocation decision they make.
How the Funds Actually Work
The mechanics of a litigation finance fund are worth understanding at a granular level, because the due diligence process is unlike anything in traditional asset management. Before committing capital to a case, a fund’s underwriting team – typically staffed with former litigators, economists, and damages experts – assesses the legal merits of the claim, the credibility of the law firm pursuing it, the likely damages range, and the defendant’s ability to pay a judgment. This process can take months for a single case.
Fund structures vary. Some funds are case-specific vehicles where investors commit capital to a single litigation matter with a defined expected timeline and recovery range. Others are portfolio funds that deploy capital across a diversified book of cases spanning multiple jurisdictions, claim types, and counterparties. Portfolio funds are generally more attractive to institutional allocators because the diversification reduces the binary nature of any single outcome and provides smoother capital deployment over the fund’s life.
Fee structures in the industry typically follow a two-and-twenty model similar to private equity, though some managers have moved toward variations that align more directly with case-level performance. Importantly, the timing of distributions is unpredictable – litigation can settle early, drag on for years through appeals, or end abruptly with a case dismissal. This illiquidity profile requires allocators to treat litigation finance the way they treat private credit or infrastructure: capital that is committed for years, not months.
One area generating serious attention is the funding of mass tort and class action litigation. These cases can involve tens of thousands of plaintiffs and damages that run into the billions. Funding a law firm pursuing a major pharmaceutical liability case or an environmental contamination claim requires a different capital commitment than funding a single commercial contract dispute, but the return profile on a successful resolution can be extraordinary. The reputational and regulatory complexity around this type of funding has historically kept institutional capital at a distance, but the appetite is growing as governance practices improve.
There is also a secondary market beginning to develop, where investors can buy and sell positions in active cases before resolution. This adds a layer of liquidity that the asset class has never had before. While still thin compared to credit or equity secondaries, the secondary market for litigation interests gives institutional allocators the option – not a guarantee – of an exit path before final judgment. That change alone removes a meaningful barrier that previously kept larger pools of capital away.
Risks That Deserve Honest Attention
The risk profile is not simple. Beyond the binary loss-of-capital risk on individual cases, there are systemic concerns that sophisticated allocators are working through. Legal system unpredictability is real – appellate courts can reverse verdicts, legislatures can cap damages, and judges can exclude expert witnesses whose testimony was central to a damages theory. A fund’s entire expected return on a case can evaporate not because the underlying facts changed, but because a procedural ruling went the wrong way. Diversification helps, but it does not eliminate this exposure.
Regulatory risk is the other factor that keeps some allocators cautious. A handful of jurisdictions have moved to restrict or require disclosure of litigation funding arrangements, and there are ongoing legislative debates in several markets about whether funders should be considered parties to litigation with attendant ethical obligations. A major regulatory restriction in a key jurisdiction could affect a fund’s ability to deploy capital or recover on existing positions. Allocators who have done the work are treating this as a known and manageable risk rather than a reason to stay out – but it is a risk that requires active monitoring, not a set-it-and-forget-it assumption.
